Sites of action of gamma-hydroxybutyrate (GHB) - A neuroactive drug with abuse potential

Journal of Toxicology - Clinical Toxicology

Volumn 35, Issue 6, 1997, Pages 581-590

  Tunnicliff, Godfrey ^a  

^a Indiana University School of Medicine Evansville   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; OXYBATE SODIUM;

BASAL GANGLION; CATALEPSY; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG MECHANISM; DRUG USE; HUMAN; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; REVIEW;

EID: 0030856829     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659709001236     Document Type: Review

References (97)

1. Krnjevic K. Significance of GABA in brain function. In: GABA Mechanisms in Epilepsy Tunnicliff G, Raess BU, eds., New York: Wiley-Liss, 1991:47-87.
2. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964;3:433-452.
3. Laborit G, Larcan A, Kind A. Le gamma-hydroxybutyrate en anesthesie neuro-chirurgicale. Neuro-chirurgie 1962;8:104-107.
4. Dyer JE. γ-Hydroxybutyrate: A health-food product producing coma and seizurelike activity. Am J Emerg Med 1991;9:321-324.
5. Stell JM, Ryan JM. Gamma-hydroxybutyrate is a new recreational drug that may lead to loss of consciousness. BMJ 1996;313:424.
6. Chin M-Y, Kreutzer RA, Dyer JE. Acute poisoning from γ-hydroxybutyrate in California. West J Med 1992;156:380-384.
7. Steele MT, Watson WA. Acute poisoning from gamma-hydroxybutyrate (GHB). Mo Med 1995;92: 354-357.
8. Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of γ-hydroxybutyrate (GHB or liquid ecstacy): A case report. BMJ 1997;314:35-36.
9. Bessman SP, Fishbein WM. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963;200:1207-1208.
10. Snead OC, Morley BJ. Ontogeny of γ-hydroxybutyric acid. I. Regional concentration in developing rat, monkey and human brain. Brain Res 1981;227: 579-589.
11. Vayer P, Ehrhardt J-D, Gobaille S, Mandel P, Maitre M. Gamma-hydroxybutyrate distribution and turnover rates in discrete brain regions of the rat. Neurochem Int 1988;12:53-59.
12. Roth RH, Giarman NJ. Conversion in vivo of γ-aminobutyric acid to γ-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 1969;18: 247-250.
13. Anderson RA, Ritzmann RF, Tabakoff B. Formation of gamma-hydroxybutyrate in brain. J Neurochem 1977;28:633-639.
14. Tabakoff B, Von Wartburg JP. Separation of aldehyde reductases and alcohol dehydrogenase from brain by affinity chromatography: Metabolism of succinic semialdehyde and ethanol. Biochem Biophys Res Commun 1975;63:957-966.
15. 14C]butyrate by rat brain: Relationship to the Krebs cycle and metabolic compartmentation of amino acids. J Neurochem 1978;30:1305-1309.
16. Weissmann-Nanopoulos D, Rumigny JF, Mandel P, Vincendon G, Maitre M. Immunochemical localization in rat brain of the enzyme that synthesizes γ-hydroxybutyric acid. Neurochem Int 1982;4: 523-529.
17. Cash CD, Maitre M, Mandel P. Purification from human brain and some properties of two NADPH-linked aldehyde reductases which reduce succinic semialdehyde to 4-hydroxybutyrate. J Neurochem 1979;33:1169-1175.
18. Rumigny JF, Maitre M, Cash C, Mandel P. Specific and nonspecific succinic semialdehyde reductases from rat brain: Isolation and properties. FEBS Letts 1980;117:111-116.
19. +-dependent reductase related to the 4-aminobutyrate shunt. J Biol Chem 1985;260: 16361-16366.
20. Cho S-W, Song M-S, Kim G-Y, Kang W-D, Choi EY, Choi SY. Kinetics and mechanism of an NADPH-dependent succinic semialdehyde reductase from bovine brain. Eur J Biochem 1993;211: 757-762.
21. +-linked alcohol oxido-reductase which catalyzes the interconversion of γ-hydroxybutyrate and succinic semialdehyde. J Neurochem 1979;32:699-712.
22. Nelson T, Kaufman EE. Developmental time courses in the brain and kidney of two enzymes that oxidize γ-hydroxybutyrate. Dev Neurosci 1994;16:352-358.
23. +-dependent oxidoreductase. J Biol Chem 1981;256:6890-6894.
24. +-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem Res 1991;16:965-974.
25. Kaufman EE, Nelson T, Fales HM, Levin DM. Isolation and characterization of a hydroxyacid-oxoacid transhydrogenase from rat kidney mitochondria. J Biol Chem 1988;263:16872-16879.
26. Jacobs C, Bojasch M, Monch E, Rating D, Siemes H, Hanefeld F. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. Clin Chim Acta 1981;111:169-178.
27. Divry P, Baltassat P, Rolland MO, Cotte J, Hermier M, Duran M, Wadman SK. A new patient with 4-hydroxybutyric aciduria, a possible defect of 4-aminobutyrate metabolism. Clin Chim Acta 1983; 129:303-309.
28. Onkenhout W, Maaswinkel-Mooij PD, Poorthuis BJHM. 4-Hydroxybutyric aciduria: Further clinical heterogeneity in a new case. Eur J Pediatrics 1989; 149:194-196.
29. Rating D, Hanefeld F, Siemes H, Kneer J, Jacobs C, Mermier M, Divry P. 4-Hydroxybutyric aciduria: A new inborn error of metabolism. I. Clinical review. J Inherited Metab Dis 1984;7(Suppl):90-92.
30. Rahbeeni Z, Ozand PT, Rashed M, et al. 4-Hydroxybutyric aciduria. Brain Dev 1994;16(Suppl):64-71.
31. Berthier M, Bonneau D, Desbordes J-M, Chevrel J, Oriot D, Jaeken J, Laborit H. Possible involvement of a gamma-hydroxybutyric acid receptor in startle disease. Acta Paediatr 1994;83:678-680.
32. Drakontides AB, Schneider JA, Funderburk WH. Some effects of sodium gamma-hydroxybutyrate on the central nervous system. J Pharmacol Exp Ther 1962;135:275-284.
33. Tunnicliff G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol 1992;23:1027-1034.
34. Winters WD, Spooner CE. Various seizure activities following gamma-hydroxybutyrate. Int J Neuropharmacol 1965;4:197-200.
35. Godschalk M, Dzoljic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in the rat by γ-hydroxybutyrate. Eur J Pharmacol 1977;44:105-111.
36. Snead OC. γ-Hydroxybutyrate model of generalized absence seizures: Further characterization and comparison with other absence models. Epilepsia 1988;29:361-368.
37. B receptors. J Neural Transm 1992;35(Suppl):155-177.
38. B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate and pentylenetetrazole models. J Pharmacol Exp Ther 1995;274: 1399-1403.
39. Giarman NJ, Schmidt KF. Some neurochemical aspects of the depressant action of γ-butyrolactone on the central nervous system. Brit J Pharmacol 1963;20:563-568.
40. Waldmeier PC, Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol 1978;49: 177-184.
41. Anden N-E, Magnusson T, Stock G. Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gamma-hydroxybutyric acid. Naunyn-Schmiedeberg's Arch Pharmacol 1973;278:363-372.
42. Walters JR, Rosh RH, Aghajanian GK. Dopaminergic neurons: Similar biochemical and histochemical effects of γ-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway. J Pharmacol Exp Ther 1973;186:630-639.
43. Bustos G, Roth RH. Effect of γ-hydroxybutyrate on the release of monoamines from the rat striatum. Brit J Pharmacol 1972;44:817-820.
44. Morgenroth VH, Walters JR, Rosh RH. Dopaminergic neurons. Alteration in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow. Biochem Pharmacol 1976;25:655-661.
45. Spano PF, Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. J Neurochem 1971;18: 1831-1836.
46. Cheramy A, Nieoullon A, Glowinski J. Stimulating effects of gamma-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. J Pharmacol Exp Ther 1977;203: 283-293.
47. Godbout R, Jelenic P, Labrie C, Schmitt M, Bourguignon J-J. Effect of gamma-hydroxybutyrate and its antagonist NCS-382 on spontaneous cell firing in the prefrontal cortex of the rat. Brain Res 1995;673:157-160.
48. Hechler V, Gobaille S, Bourguignon J-J, Maitre M. Extracellular events induced by γ-hydroxybutyrate in striatum: A microdialysis study. J Neurochem 1991;56:938-944.
49. Howard SG, Feigenbaum JJ. Effect of γ-hydroxybutyrate on central dopamine release in vivo. Biochem Pharmacol 1997;53:103-110.
50. Diana M, Mereu G, Mura A, Fadda F, Passino N, Gessa G. Low doses of γ-hydroxybutyric acid stimulate the firing fate of dopaminergic neurons in unanesthetized rats. Brain Res 1991;566:208-211.
51. Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth CG, Mandel P, Vincendon G, Maitre M. High affinity binding site for γ-hydroxybutyric acid in rat brain. Life Sci 1982;30:953-961.
52. Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon J-J. A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J Pharmacol Exp Ther 1990;255:657-663.
53. Cash CD, Hechler V, Mersel M, Maitre M. Kinetic characterization and solubilization of γ-hydroxybutyrate from rat brain. Neurosci Lett 1996;209: 25-28.
54. Maitre M, Rumigny JF, Mandel P. Positive cooperativity in high affinity binding sites for γ-hydroxybutyric acid in rat brain. Neurochem Res 1983;8:113-120.
55. 3H]hydroxybutyrate binding sites as determined by quantitative autoradiography. J Neurochem 1987;49:1025-1032.
56. Ratomponirina C, Hode Y, Hechler V, Maitre M. γ-Hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertussis toxin. Neurosci Lett 1995;189:51-53.
57. B) receptor in rat brain. Biochem Pharmacol 1996;52:1235-1243.
58. Godbout R, Mantz J, Pirot S, Glowinski J, Thierry A-M. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: Electrohysiological and pharmacological characterization. J Pharmacol Exp Ther 1991;258:728-738.
59. Chrapusta SJ, Karoum F, Egan MF, Wyatt RJ. γ-Butyrolactone-sensitive and -insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions. Eur J Pharmacol 1992; 222:129-135.
60. B-receptor antagonist, CGP 35348, antagonises γ-hydroxybutyrate-and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. J Neural Transm 1996;103:1255-1263.
61. B receptors and their significance in mammalian pharmacology. Trends Pharmacol Sci 1989;10:401-407.
62. B receptors. Eur J Pharmacol 1992;212:291-294.
63. B receptor-mediated hyperpolarization. Neuroscience 1995;66:133-141.
64. B receptor agonist. Eur J Pharmacol 1997;321:67-75.
65. +-dependent uptake system for γ-hydroxybutyrate in membrane vesicles prepared from rat brain. J Neurochem 1982;38:1570-1575.
66. Tunnicliff G. Stimulation of mouse brain γ-hydroxybutyric acid transport by pyridoxal 5'-phosphate. Pharmacology 1994;49:271-277.
67. Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: A new anesthetic adjuvant. Anesth Analg Curr Res 1962;41:721-726.
68. Solway J, Sadove MS. 4-Hydroxybutyrate: A clinical study. Anesth Analg Curr Res 1965;44:532-539.
69. Aldrete JA, Barnes DP. 4-Hydroxybutyrate anesthesia for cardiovascular surgery. Anesthesia 1968;23: 558-565.
70. Vickers MD. Gamma-hydroxybutyric acid. Int Anaesth Clin 1969;7:75-89
71. Brown TC. Gamma-hydroxybutyrate in paediatric anaesthesia. Aust NZ J Surg 1970;40:94-99.
72. Entholzner E, Mielke L, Pichlmeier R, Weber F, Schneck H. EEG changes during sedation with gamma-hydroxybutyric acid. Anaesthesist 1995;44: 345-350.
73. Mamelak M, Escruiu JM, Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 1977;12:273-288.
74. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroenceph Clin Neurophysiol 1966;20: 506-512.
75. Lapierre O, Montplaisir J, Lamarre M, Bedard MA. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: Further considerations on REM sleep-triggering mechanisms. Sleep 1990;13:24-30.
76. Broughton R, Mamelak M. The treatment of narcolepsy-catalepsy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6:1-6.
77. Scharf MB, Brown D, Woods M, Brown L, Hirschowitz J. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatr 1985;46:222-225.
78. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with γ-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986;9:285-289.
79. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gamma-hydroxybutyrate and narcolepsy: A double-blind placebo-controlled study. Sleep 1993;16:216-220.
80. Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC. The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study. Sleep 1990;13:479-490.
81. Snead OC, Bearden LJ. Naloxone overcomes the dopaminergic, EEG and behavioral effects of γ-hydroxybutyrate. Neurology 1980;30:832-838.
82. Schmidt C, Gobaille S, Hechler V, Schmidt M, Bourguignon J-J, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a γ-hydroxybutyrate receptor antagonist. Eur J Pharmacol 1991;203:393-397.
83. Fadda F, Argiolas A, Melis MR, De montis G, Gessa GL. Suppression of voluntary ethanol consumption in rats by gamma-butyrolactone. Life Sci 1989;32: 1471-1477.
84. Fadda F, Mosca E, Colombo G, Gessa GL. Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats. Alcohol Alcoholism 1989;24:447-451.
85. Gallimberti L, Fern M, Ferrara SD, Fadda F, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double blind study. Alcohol Clin Exp Res 1992;16:673-676.
86. Gallimberti L, Canton G, Gentile N, Ferri M, Cibin M, Ferrara SD, Fadda F, Gessa GL. Gamma-hydroxybutyric acid for the treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-789.
87. Gallimberti L, Cibin M, Pagnin P, Sabbion R, Pani PP, Pirastu R, Ferrara SD, Gessa GL. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993;9:77-81.
88. Gessa GL, Dianna M, Fadda F, Colombo G. Gamma-hydroxybutyric acid (GHB) for treatment of ethanol dependence. Eur Neuropsychopharmacol 1993;3:224-225.
89. Takahara J, Yunoki S, Yakushiji W, Yamane, Oruji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977;44:1014-1017.
90. Gerra G, Marcato A, Fertonani Affini G, et al. Gamma-hydroxybutyric acid (GHB) and neuro-endocrine function in humans. Neuroendocrinol Lett 1994;16:55-63.
91. Ross TM. Gamma-hydroxybutyrate overdose: Two cases illustrate the unique aspects of this dangerous recreational drug. J Em Nursing 1995;21:374-376.
92. Louagie HK, Verstraete AG, De Soete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid and ethanol. J Toxicol Clin Toxicol 1997;35:591-594.
93. Carter J, Mofenson H, Caraccio T, et al. Gamma-hydroxybutrate use - New York and Texas, 1995-1996. Morb Mortal Wkly Rep 1997;46:281-283.
94. Marwick C. Coma-inducing drug GHB may be reclassified. JAMA 1997;277:1505-1506.
95. Galloway GP, Frederick SL, Staggers F. Physical dependence on sodium oxybate. Lancet 1994;343:57.
96. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: An emerging drug of abuse that causes physical dependence. Addiction 1997;92:89-96.
97. Friedman J, Westlake R, Furman M. "Grievous bodily harm": Gamma-hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996;46:469-471.